20:54 IST
NSE
Earnings Call
Piramal Pharma Investor Presentation: Key Takeaways
Piramal Pharma started FY27 with 17% revenue growth and 72% EBITDA expansion. Momentum was driven by CDMO recovery and power brands.
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
1 announcement with these filters
Piramal Pharma started FY27 with 17% revenue growth and 72% EBITDA expansion. Momentum was driven by CDMO recovery and power brands.